

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI210499

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	Release of Security Interest in Intellectual Property Collateral at Reel/Frame No. 49081/0335	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
Midcap Financial Trust, as Agent		05/03/2024
<b>RECEIVING PARTY DATA</b>		
<b>Company Name:</b>	Gossamer Bio, Inc.	
<b>Street Address:</b>	3013 Science Park Road, Suite 200	
<b>City:</b>	San Diego	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	92121	
<b>Company Name:</b>	Gossamer Bio Services, Inc.	
<b>Street Address:</b>	3013 Science Park Road, Suite 200	
<b>City:</b>	San Diego	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	92121	
<b>Company Name:</b>	GB001, Inc.	
<b>Street Address:</b>	3013 Science Park Road, Suite 200	
<b>City:</b>	San Diego	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	92121	
<b>Company Name:</b>	GB002, Inc.	
<b>Street Address:</b>	3013 Science Park Road, Suite 200	
<b>City:</b>	San Diego	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	92121	
<b>Company Name:</b>	GB003, Inc.	
<b>Street Address:</b>	3013 Science Park Road, Suite 200	
<b>City:</b>	San Diego	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	92121	
<b>Company Name:</b>	GB004, Inc.	
<b>Street Address:</b>	3013 Science Park Road, Suite 200	

<b>City:</b>	San Diego
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121
<b>Company Name:</b>	GB005, Inc.
<b>Street Address:</b>	3013 Science Park Road, Suite 200
<b>City:</b>	San Diego
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121
<b>Company Name:</b>	GB007, Inc.
<b>Street Address:</b>	3013 Science Park Road, Suite 200
<b>City:</b>	San Diego
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121
<b>Company Name:</b>	GB008, Inc.
<b>Street Address:</b>	3013 Science Park Road, Suite 200
<b>City:</b>	San Diego
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121

**PROPERTY NUMBERS Total: 30**

<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	7858640
<b>Patent Number:</b>	8173812
<b>Patent Number:</b>	8394830
<b>Patent Number:</b>	8394836
<b>Patent Number:</b>	9649305
<b>Patent Number:</b>	10010542
<b>Patent Number:</b>	9624239
<b>Patent Number:</b>	9284318
<b>Patent Number:</b>	9796716
<b>Patent Number:</b>	9795608
<b>Patent Number:</b>	9447102
<b>Patent Number:</b>	9822120
<b>Patent Number:</b>	8791272
<b>Patent Number:</b>	8759386
<b>Patent Number:</b>	9206164
<b>Patent Number:</b>	8859770
<b>Patent Number:</b>	7812160
<b>Patent Number:</b>	7960393

Property Type	Number
Patent Number:	7750014
Patent Number:	8507005
Patent Number:	8278310
Patent Number:	8314116
Patent Number:	8324229
Patent Number:	8541419
Application Number:	16302553
Application Number:	62809255
Application Number:	15577136
Application Number:	15772919
Application Number:	15772916
Application Number:	16326082

#### CORRESPONDENCE DATA

**Fax Number:** 2138918763

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2138918886

**Email:** rhonda.deleon@lw.com

**Correspondent Name:** Rhonda DeLeon

**Address Line 1:** Latham & Watkins LLP, 355 South Grand Avenue

**Address Line 4:** Los Angeles, CALIFORNIA 90071-1560

**ATTORNEY DOCKET NUMBER:** 061974-0003

**NAME OF SUBMITTER:** Rhonda DeLeon

**SIGNATURE:** Rhonda DeLeon

**DATE SIGNED:** 05/03/2024

#### Total Attachments: 7

source=MidCap - Gossamer - IP Release (Executed)#page1.tif

source=MidCap - Gossamer - IP Release (Executed)#page2.tif

source=MidCap - Gossamer - IP Release (Executed)#page3.tif

source=MidCap - Gossamer - IP Release (Executed)#page4.tif

source=MidCap - Gossamer - IP Release (Executed)#page5.tif

source=MidCap - Gossamer - IP Release (Executed)#page6.tif

source=MidCap - Gossamer - IP Release (Executed)#page7.tif

**RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This Release of Security Interest in Intellectual Property, dated as of May 3, 2024, is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, (“**Agent**”), in favor of **GOSSAMER BIO, INC.**, a Delaware corporation, **GOSSAMER BIO SERVICES, INC.**, a Delaware corporation, **GB001, INC.**, a Delaware corporation, **GB002, INC.**, a Delaware corporation, **GB003, INC.**, a Delaware corporation, **GB004, INC.**, a Delaware corporation, **GB005, INC.**, a Delaware corporation, **GB007, INC.**, a Delaware corporation, and **GB008, INC.**, a Delaware corporation (each, a “**Grantor**” and collectively, the “**Grantors**”):

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of May 2, 2019 (as amended, modified, restated, replaced or supplemented from time to time, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on May 3, 2019 at Reel/Frame Nos. 049081/0335 (Patents) and 6636/0422 (Trademarks), each Grantor granted to Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of such Grantor’s intellectual property, including those listed on Exhibits A through C thereto;

WHEREAS, the Grantors have requested that Agent release its security interest in and to the patent assets, including without limitation those more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to the trademark assets, including without limitation those more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantors have requested that Agent release its security interest in and to all other intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, collectively, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at the Grantors’ sole cost and expense, hereby releases all of Agent’s right, title and interest in and to the Released IP Collateral, including the issued patents, patent applications, trademark registrations, and trademark applications set forth in Schedules A and B attached hereto and incorporated herein by reference, and agrees that all the security interest in the Released IP Collateral is hereby discharged, terminated and released.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, Agent has caused this Release of Security Interest in Intellectual Property to be duly executed and delivered by its duly authorized officer as of the date first written above.

AGENT:

MIDCAP FINANCIAL TRUST  
as Agent

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:   
Name: Maurice Amsellem  
Title: Authorized Signatory

Schedule A

Patents

Owner	Name/Identifier	Application No.	Publication No.	Patent No.	Filing Date	Expiration Date
GB001, Inc.	QUINOLINES AND THEIR THERAPEUTIC USE	12/066,603	2009-0156600	7,858,640	12-Mar-08	10-Oct-26
GB001, Inc.	QUINOLINES AND THEIR THERAPEUTIC USE	12/531,935	2010-0144787	8,173,812	18-Sep-09	Terminal disclaimer (TD) over 7,858,640
GB001, Inc.	QUINOLINES AND THEIR THERAPEUTIC USE	13/435,242	2012-0184579	8,394,830	30-Mar-12	3-Apr-28
GB001, Inc.	INDOLES AND THEIR THERAPEUTIC USE	12/746,104	2011-0071175	8,394,836	3-Jun-10	9-Dec-29
GB001, Inc.		16/302,553	unpublished		16-Nov-18	
GB001, Inc.	TREATMENT OF ASTHMA PATIENTS HAVING HIGH BASELINE FE <sub>NO</sub> LEVELS	62/809,255	unpublished		22-Feb-19	
Advanced Cancer Therapeutics, LLC	PEKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC	14/388,983	2015-0064175	9,649,305	29-Sep-14	22-Oct-33
GB ACT, INC. (now known as GB003, Inc.)	PEKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC	15/482,956	2017-0258783	10,010,542	10-Apr-17	14-Mar-33
GB005, Inc.	PROTEIN KINASE INHIBITORS	14/009,635	2014-0045833	9,624,239	28-Oct-13	12-May-33
GB005, Inc.	PROTEIN KINASE INHIBITORS	14/008,977	2015-0210696	9,284,318	18-Feb-15	25-Jul-32
GB005, Inc.	SELECTIVE INHIBITORS OF TEC AND SRC PROTEIN KINASE FAMILIES	14/404,497	2015-0191473	9,796,716	28-Nov-14	28-May-33

PATENT

REEL: 067310 FRAME: 0312

**PATENT**

**REEL: 067310 FRAME: 0313**

GB005, Inc.	PROTEIN KINASE INHIBITORS	15/262,193	2016-0375027	9,795,608	12-Sep-16	TD over 9,447,102
GB005, Inc.	PROTEIN KINASE INHIBITORS	14/412,982	2015-0344478	9,447,102	5-Jan-15	3-Jul-33
GB005, Inc.	PROTEIN KINASE INHIBITORS	15/037,923	2016-0280711	9,822,120	19-May-16	20-Nov-34
GB005, Inc.	Inhibitors of the TEC Kinase Enzyme Family	15/577,136	2018-0179210		27-Nov-17	
GB005, Inc.	NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS	15/772,919	2018-0319781		2-May-18	
GB005, Inc.		15/772,916	unpublished		9-Sep-16	
GB005, Inc.	SPIROCyclic CONTAINING COMPOUNDS AND PHARMACEUTICAL USES THEREOF	16/326,082	unpublished		15-Feb-16	
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS	13/012,244	2012-0028938	8,791,272	24-Jan-11	17-Jul-30
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS	13/353,621	2013-0023576	8,759,386	19-Jan-12	13-Nov-31
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS	14/006,170	2014-0113917	9,206,164	15-Mar-12	12-Oct-32
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	Process for preparing [4,6-bis-dimethylamino- 2-[4-(4- trifluoromethylbenzoylamino)benzyl]pyrimidin- 5-yl]acetic acid	14/116,876	2014-0187779	8,859,770	7-May-12	7-May-32

GB007, Inc.)						
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2	10/554,668	2007-0129355	7,812,160	14-Apr-04	17-Oct-26
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2	12/868,663	2010-0322980	7,960,393	25-Aug-10	14-Apr-24
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	IMIDAZO[1,2-C]PYRIMIDINYLACETIC ACID DERIVATIVES	10/585,429	2009-0012102	7,750,014	19-Jan-05	19-Oct-27
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	PARTICULATES OF A CRTH2 ANTAGONIST	12/665,706	2011-0052701	8,507,005	18-Jun-08	15-Aug-29
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	AMINE SALTS OF A CRTH2 ANTAGONIST	12/665,705	2011-0034482	8,278,310	18-Jun-08	18-Jun-28
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	2-S-BENZYL SUBSTITUTED PYRIMIDINES AS CRTH2 ANTAGONISTS	12/679,893	2010-0240685	8,314,116	24-Sep-08	29-May-29
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	ALKYLTHIO PYRIMIDINES AS CRTH2 ANTAGONISTS	12/679,895	2010-0298361	8,324,229	24-Sep-08	29-May-29

PATENT

REEL: 067310 FRAME: 0314



Inc., (now known as GB007, Inc.)						
Actimis Pharmaceuticals, Inc., (now known as GB007, Inc.)	ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS	13/061,921	2011-0172250	8,541,419	1-Sep-09	27-Oct-29

**PATENT**

**REEL: 067310 FRAME: 0315**

Schedule B

Trademarks

Owner	Name/Identifier	Application No.	Filing Date	Expiration Date
Gossamer Bio, Inc.	GOSSAMERBIO	88/387765	16-April-19	N/A
Gossamer Bio, Inc.	GOSSAMERBIO Stylized & Circle Design (Blk/Wb)	88/387761	16-April-19	N/A
Gossamer Bio, Inc.	GOSSAMERBIO Stylized & Circle Design (Blk/Wb)	88/387758	16-April-19	N/A

PATENT

REEL: 067310 FRAME: 0316